Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly
- PMID: 2229321
- DOI: 10.1210/jcem-71-6-1658
Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly
Abstract
Gastrointestinal side-effects of prolonged therapy (greater than 2 yr) with the long-acting somatostatin analog octreotide were studied in 10 acromegalic patients. After 2 yr of therapy, 6 of 10 patients had newly developed gallstones, complicated by cholangitis and jaundice in 1. Serum vitamin B-12 concentrations declined in all 10 patients [from 380 +/- 32 to 172 +/- 21 pmol/L (mean +/- SE); P = 0.023] and became abnormally low in 4. Gastric biopsy specimens, obtained during gastroscopy (9 patients), showed moderate to severe active gastritis, with damage to the superficial and deeper layers of the mucosa in 9 of 9 and focal atrophy in 7 of 9 patients. Campylobacter pylori was found in the antral mucosa in 8 of 9 patients. Although information is lacking on similar studies in untreated acromegalic patients, we suggest that patients receiving chronic octreotide therapy be closely monitored for these and possible other side-effects related to gastrointestinal actions of octreotide.
Similar articles
-
Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide.Clin Endocrinol (Oxf). 1995 Dec;43(6):683-7. doi: 10.1111/j.1365-2265.1995.tb00535.x. Clin Endocrinol (Oxf). 1995. PMID: 8736269
-
Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.J Clin Endocrinol Metab. 1993 Jul;77(1):157-62. doi: 10.1210/jcem.77.1.8325938. J Clin Endocrinol Metab. 1993. PMID: 8325938
-
Prevalence of gastritis in patients with acromegaly: untreated and during treatment with octreotide.Clin Endocrinol (Oxf). 1992 Sep;37(3):227-32. doi: 10.1111/j.1365-2265.1992.tb02315.x. Clin Endocrinol (Oxf). 1992. PMID: 1424205
-
Proceedings of the workshop, "Practical approaches to the diagnosis and treatment of acromegaly".Metabolism. 1992 Sep;41(9 Suppl 2):87-90. doi: 10.1016/0026-0495(92)90039-d. Metabolism. 1992. PMID: 1518440 Review.
-
Octreotide is effective in acromegaly but often results in cholelithiasis.Ann Intern Med. 1990 Feb 1;112(3):159-60. doi: 10.7326/0003-4819-112-3-159. Ann Intern Med. 1990. PMID: 2404444 Review. No abstract available.
Cited by
-
Association of the Somatostatin Analog Octreotide With Magnetic Nanoparticles for Intraocular Delivery: A Possible Approach for the Treatment of Diabetic Retinopathy.Front Bioeng Biotechnol. 2020 Feb 25;8:144. doi: 10.3389/fbioe.2020.00144. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32158755 Free PMC article.
-
Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.Support Care Cancer. 2013 Oct;21(10):2817-24. doi: 10.1007/s00520-013-1860-1. Epub 2013 Jun 4. Support Care Cancer. 2013. PMID: 23732621
-
The Role and Diagnostic Potential of Insulin-like Growth Factor 1 in Diabetic Retinopathy and Diabetic Macular Edema.Int J Mol Sci. 2025 Apr 22;26(9):3961. doi: 10.3390/ijms26093961. Int J Mol Sci. 2025. PMID: 40362202 Free PMC article. Review.
-
Octreotide induced prolongation of colonic transit increases faecal anaerobic bacteria, bile acid metabolising enzymes, and serum deoxycholic acid in patients with acromegaly.Gut. 2005 May;54(5):630-5. doi: 10.1136/gut.2003.028431. Gut. 2005. PMID: 15831907 Free PMC article.
-
Use of octreotide acetate for control of symptoms in patients with islet cell tumors.World J Surg. 1993 Jul-Aug;17(4):504-10. doi: 10.1007/BF01655110. World J Surg. 1993. PMID: 8395751 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources